When was Evotec founded?

Evotec was founded in 1993 and raised its 1st funding round 5 years after it was founded.

Where is Evotec located?

Evotec is headquartered in Hamburg, Germany. It is registered at Essener Bogen 7, DE-22419 HAMBURG.

Who is the current CEO of Evotec?

Werner Lanthaler of Evotec. They are also an angel investors in 1 startup.

How many employees does Evotec have?

As of Mar 31, 2026, the latest employee count at Evotec is 4845.

Is Evotec a funded company?

Evotec is a funded company, having raised a total of $25M across 23 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Mar 30, 1998.

When was the latest funding round of Evotec?

Evotec's latest funding was a $***** Grant (prize money) round on Jan 08, 2026, with participation from 1 investor.

Where does Evotec rank among its competitors?

Evotec ranks 1st amongst 159 active competitors, of which 64 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Evotec, which secured an undisclosed amount in Jan, 2026.

Who are the top competitors of Evotec?

Evotec's top competitors include DNAnexus, Insitro and Cytel. Among them, Evotec secured the most recent funding round in January, 2026.

Evotec - 2026 Company Profile, Team, Funding & Competitors

Company Details

Website: www.evotec.com/
Social
Registered Address: Essener Bogen 7, DE-22419 HAMBURG

Key Metrics

Founded Year

1993

Location

Hamburg, Germany

Stage

Public

Total Funding

$25M in 23 rounds

Latest Funding Round

Grant (prize money), Jan 08, 2026, $*****

Investors

Omega Funds & 21 more

Ranked

1^st among 159 active competitors

Employee Count

4,845 as on Mar 31, 2026

Investment & Acquisitions

Tubulis Technologies & 33 more

Similar Companies

DNAnexus & 183 more

Exit Details

Public

View Evotec's full profile

Evotec is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Evotec International Gmbh CIN: HRB72242 , Germany, Active	Aug 18, 1999	-	252 (As on Dec 31, 2020)
EVOTEC INTERNATIONAL GMBH CIN: 831855142 , Norway, Active	May 24, 1999	-	-
EVOTEC (US) INC. CIN: 943353740 , United States, Active	Dec 31, 1999	-	729 (As on Dec 31, 2024)	-

Evotec got listed on Nov 10, 1999.

Click here to take a look at Evotec's IPO in detail

Evotec has raised a total funding of $25M over 23 rounds. Its first funding round was on Mar 30, 1998. Its latest funding round was a Grant (prize money) round on Jan 08, 2026 for $*****. 1 investor participated in its latest round. Evotec has 22 institutional investors.

Here is the list of recent funding rounds of Evotec:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 08, 2026	8853395	Grant (prize money)	7844474	8795587	2866324	9615425
May 08, 2025	3326650	Grant (prize money)	1201225	8536152	9639610	Gates
Apr 11, 2025	1498326	Grant (prize money)	4694543	7413213	5854439	Military Health

Access funding benchmarks and valuations. Sign up today!

View details of Evotec's funding rounds and investors

Evotec's employee count trend

Evotec has 4,845 employees as of Mar 26. Here is Evotec's employee count trend over the years:

Uncover Evotec's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Evotec include DNAnexus, Insitro and Cytel. Here is the list of Top 10 competitors of Evotec, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Evotec 1993, Hamburg (Germany), Public	Provider of drug discovery alliance and development services for biopharma sector	$25M	Omega Funds, Mubadala & 20 others	74/100
2nd	DNAnexus 2009, Mountain View (United States), Series H	Provider of cloud-based genome informatics & data management platform	$473M	Google Ventures, TPG & 21 others	70/100
3rd	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Foresite Capital & 18 others	70/100
4th	Cytel 1987, Cambridge (United States), Acquired	Provider of data analysis and statistical solutions for the life sciences industry	$2M	New Mountain Capital, Autonomy Ventures & 3 others	66/100
5th	Immunai Technologies 2018, United States, Series B	Developer of next-generation of immunomodulatory therapeutics	$295M	Viola Group, Catalio Capital Management & 14 others	66/100
6th	Metagenomi 2016, Berkeley (United States), Public	Digital gene editing technologies for drug development	$376M	Humboldt Fund, RA Capital Management & 22 others	65/100
7th	Asimov 2017, Boston (United States), Series B	Provider of integrated suite for advanced genetic design and manufacturing	$209M	Andreessen Horowitz, CPP Investments & 11 others	64/100
8th	NewLimit 2022, San Francisco (United States), Series B	Developer of epigenetic reprogramming medicines for aging-related diseases and healthspan extension	$247M	Kleiner Perkins, Lilly & 17 others	64/100
9th	Relation Therapeutics 2020, London (United Kingdom), Seed	AI-based drug development tools for researchers	$116M	DCVC, Magnetic Ventures & 9 others	64/100
10th	Kinomica 2017, Macclesfield (United Kingdom), Series A	Provider of a bioinformatics platform for the development of precision medicine	$5.16M	BGF, Longwall Venture Partners & 15 others	63/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Evotec's competitors? Click here to see the top ones

Evotec has made 23 investments in companies including Tubulis Technologies and Aeovian Pharmaceuticals. Evotec has also acquired 11 companies including Central Glass and Central Glass.

Here is the list of investments & acquisitions:

Filter this list

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Mar 14, 2024	Investments	Tubulis Technologies	2015	Munich (Germany)
Dec 22, 2023	Investments	Aeovian Pharmaceuticals	2012	San Francisco (United States)
Dec 01, 2022	Investments	Carrick Therapeutics	2015	Oxford (United Kingdom)